Total 208, page 4/11
| No. | Organization | Therapeutic Area | Product Type | Title |
|---|---|---|---|---|
| 98 | Adecto Pharmaceuticals | Oncology | Antibody | ADAM8_TNBC |
| 97 | CRUK | Oncology | Cell therapy | LMP2-TCR transduction therapy_Cancer |
| 96 | University of California, San Diego | Neurology, CNS disease | Small molecule | α-synuclein inhibitor_Neurodegenerative Disorders |
| 95 | University of California, San Francisco | Immunology, Oncology | Small molecule | IRE1α, IRE1β_Cancer, Autoimmune disease |
| 94 | The Ohio State University | Metabolic disease | Small molecule | Erβ agonist_NASH |
| 93 | The Ohio State University | Oncology | Small molecule | GULT inhibitor_Cancer |
| 92 | LifeArc | Oncology | Small molecule | PAICS inhibitor_Cancer |
| 91 | Imperial College London | Oncology | Small molecule | Dual HKMT inhibitor_Cancer |
| 90 | Oxford University | Immunology | Peptide | Complement C5 inhibitor_Immune diseases |
| 89 | Alborada Drug Discovery Institute | Neurology, CNS disease | Small molecule | PI5P4 kinase Inhibitors_Neurodegenerative disease |
| 88 | CD3 | Oncology | Small molecule | Nuclear Import (KPNB1)_Cancer |
| 87 | Oxford University | Oncology | Antibody | IL22RA1high, mtKRAS_Colorectal cancer |
| 86 | Oxford University | Oncology | Gene therapy | Control of gene expression_Cancer |
| 85 | Oxford University | Genetic disorders | Gene therapy | Logical control of CRISPR gene editing system |
| 84 | Oxford University | Immunology | Peptide | CIRp-A_Complement-mediated disease |
| 83 | Oxford University | Oncology | Cell therapy | Dendritic cells_Cancer |
| 82 | Oxford University | Various diseases | Nucleotide | Locked Nucleic Acid |
| 81 | Oxford University | Oncology | Peptide | IGF2-TRAP_Cancer |
| 80 | Oxford University | Oncology | Small molecule | Ras inhibitor_Ras mutation related Cancer |
| 79 | LifeArc | Cardiovascular disease | Antibody | Anti-tPA antibody_Stroke, Cardiovascular disease |
